Webinar: Discussion of 6-month MDR-TB treatment

RESIST-TB will host a webinar on 14 April 2022 on the latest results in the recent studies reporting on pretomanid-containing regimens, ZeNiX and TB-PRACTECAL, for the treatment of multidrug-resistant TB (MDR-TB).

For further details about the event and how to connect, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By RESIST-TB

Published: April 12, 2022, 9:59 p.m.

Last updated: April 13, 2022, 9:42 p.m.

Print Share